Previous 10 | Next 10 |
The investment firm All Blue Capital announced on Tuesday that Alan Barge, former head of Oncology at AstraZeneca (AZN), has agreed to advise the company in its recent proposal to acquire clinical-stage biotech, Zymeworks (NYSE:ZYME). As Oncology Drug Development Advisor, Dr. Barge will ...
ALL BLUE CAPITAL ANNOUNCES LEADERSHIP TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS, INC. PR Newswire Alan Barge , MD, Oncology and Biopharmaceutical Drug Development Expert, Former Head of Oncology at AstraZeneca, Recently Joined All Blue as Oncology Drug Developme...
April saw the worst monthly performance for the NASDAQ since November of 2008 when the country was in the depths of the financial crisis. The war in Ukraine entered its third month and inflation shows no signs as abating as 1st quarter GDP growth was negative. What will the month ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short squeeze stocks are once again in focus this week as the economy prepares for this month’s planned interest rate hike. Indeed, as the bears are out and about, it’s no surprise to see short squeeze candida...
Stocks plunged on Friday, hurt by a negative reaction to the latest round of tech earnings, with Amazon posting its biggest single-day loss in more than 15 years. The Nasdaq led the decline, falling 4.2% and recording its worst monthly performance since the Financial Crisis. Even amid a wash ...
Gainers: GTY Technology Holdings (GTYH) +114%. Vaxxinity (VAXX) +57%. Zymeworks (ZYME) +35%. Redbox Entertainment (RDBX) +33%. Finch Therapeutics Group (FNCH) +29%. Opiant Pharmaceuticals (OPNT) +29%. Puyi (PUYI) +27%. Cyngn (CYN) +24%. Clearwater (CLW) +24%. Anixa Biosciences (ANIX) +21%. Lo...
Zymeworks (NYSE:ZYME) board is likely to be reject All Blue Falcons $10.50/share bid, according to Wells Fargo, which argues that it undervalues the company. All Blue Falcons bid may accelerate potential partnership talks and a White Knight could show up with a higher price, though a bet...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zymeworks (NYSE: ZYME ) stock is taking off on Friday after the company revealed an unsolicited offer from private equity firm All Blue Falcons FZE . Source: Ruslan Ivantsov / Shutterstock.com All Blue Falcon...
Zymeworks (NYSE: ZYME) stock is shooting through the roof today in response to a juicy buyout offer from a division of All Blue Capital. The Dubai-based private equity group appears to be reacting to new clinical trial data for the company's cancer drug candidate, zanidatamab. The s...
Gainers: Finch Therapeutics (FNCH) +46%. Zymeworks (ZYME) +44%. Lantheus (LNTH) +13%. BeiGene (BGNE) +12%. Inari Medical (NARI) +11%. Losers: Accolade (ACCD) -55%. Aldeyra Therapeutics (ALDX) -15%. Venus Concept (VERO) -14%. Bio...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...